Taipei, Taiwan, 18 June, 2025 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795) today announced that its subsidiary, Lotus International Pte. Ltd. (“Lotus SG”), has entered into an asset purchase agreement with a Vietnamese pharmaceutical company for the acquisition of the trademark, marketing authorization, assignment of manufacturing supply agreements related to five drug products in Vietnam. Subject to fulfillment of the closing conditions in the agreement, the closing is expected to be in 3Q 2025.
The portfolio covers a wide range of therapeutic areas, including hematology, CV, oncology and anti-inflammation. Sales of these products in Vietnam was around USD 8 million in 2024 and saw a compound annual growth rate (CAGR) of 22% in 2022-24, underscoring their strong commercial potential in the local market.
Petar Vazharov, Chief Executive Officer of Lotus Pharmaceutical, commented:
"This acquisition marks another important step in expanding Lotus’ critical mass in Southeast Asia. We are excited to bring this portfolio of high-quality and affordable medicines to more patients. The strong historical growth of these products reinforce our confidence in their future success, and this deal aligns with our strategy to accelerate growth through strategic acquisitions in fast-growing emerging markets."
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.
Media Inquiries:
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com